Excerpt from Hydatidiform MoleSynonyms, Key Words, and Related Terms: gestational trophoblastic disease, placental site trophoblastic tumor, molar pregnancy, complete mole, partial mole, cystic mole, hydatidiform mole, choriocarcinoma, invasive mole, trophoblastic hyperplasia, nonmetastatic trophoblastic disease, theca lutein cysts, diet deficient in animal fat, diet deficient in carotene, hyperemesis, trophoblastic malignancy, vaginal bleeding, hyperthyroidism, absence of fetal Please click here to view the full topic text: Hydatidiform MoleBackgroundGestational trophoblastic disease encompasses several disease processes that originate in the placenta. These include complete and partial moles, placental site trophoblastic tumors, choriocarcinomas, and invasive moles. Almost all women with malignant gestational trophoblastic disease can be cured with preservation of reproductive function. The following discussion is limited to hydatidiform moles (complete and partial). PathophysiologyA complete mole contains no fetal tissue. Ninety percent are 46,XX, and 10% are 46,XY.1, 2 Complete moles can be divided into 2 types:
With a partial mole, fetal tissue is often present. Fetal erythrocytes and vessels in the villi are a common finding. The chromosomal complement is 69,XXX or 69,XXY.8 This results from fertilization of a haploid ovum and duplication of the paternal haploid chromosomes or from dispermy. Tetraploidy may also be encountered. As in a complete mole, hyperplastic trophoblastic tissue and swelling of the chorionic villi occur. FrequencyUnited StatesBy studying elective pregnancy terminations, hydatidiform moles were determined to occur in approximately 1 in 1200 pregnancies.9 InternationalThe reported frequency of hydatidiform mole varies greatly. Some of this variability can be explained by differences in methodology (eg, single hospital vs population studies, identification of cases). The reported frequencies range from 1 in 100 pregnancies in Indonesia to 1 in 200 pregnancies in Mexico to 1 in 5000 pregnancies in Paraguay.10 The study of pathologic material from first- and second-trimester abortions established a frequency of complete and partial hydatidiform moles in Ireland of 1 per 1945 pregnancies and 1 per 695 pregnancies, respectively.11 Mortality/MorbidityA hydatidiform mole is considered malignant if metastases or destructive invasion of the myometrium (ie, invasive mole) occurs, or when the serum hCG levels plateau or rise during the period of follow-up and an intervening pregnancy is excluded. Malignancy (see eMedicine's article Gestational Trophoblastic Neoplasia) is diagnosed in 15-20% of patients with a complete hydatidiform mole and 2-3% of partial moles.12, 13 Lung metastases are found in 4-5% of patients with a complete hydatidiform mole and rarely in cases of partial hydatidiform moles.14, 15 RaceDifferences in the frequency of hydatidiform moles between ethnic groups have been reported internationally.10, 16 In the United States, comparison of frequency of hydatidiform moles in African Americans and Caucasians have yielded conflicting results.16 If differences exist, whether they are due to genetic differences or environmental factors is not clear. SexHydatidiform mole is a disease of pregnancy and therefore a disease of women. AgeHydatidiform mole is more common at the extremes of reproductive age. Women in their early teenage or perimenopausal years are most at risk.17, 18, 19, 10, 16 Women older than 35 years have a 2-fold increase in risk. Women older than 40 years experience a 5- to 10-fold increase in risk compared to younger women. Parity does not affect the risk. Please click here to view the full topic text: Hydatidiform Mole |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |